Filing Details
Replimune Group, Inc. (NASDAQ:REPL) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on October 28, 2026.
The Healthcare company reported Q0 revenue of .
10q filedNASDAQ:REPL
Replimune Group, Inc. (REPL) Files Quarterly Report for Q0
Replimune Group, Inc. (NASDAQ:REPL) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on October 28, 2026.
At publication ·
What changed
Replimune Group, Inc. (NASDAQ:REPL) · 10q filed
- Form
- 10-Q
At a glance
Key takeaways
- Replimune Group, Inc. filed its quarterly 10-Q report on October 28, 2026, providing unaudited financial statements and management commentary.
- The healthcare company's stock trades at $16.06 with a market capitalization of $774.6 million.
- The 10-Q filing contains timely information about emerging trends, updated risk factors, and changes in business conditions since the last filing.
Market Context
Replimune Group, Inc.'s stock currently trades at $16.06 with a market capitalization of $774.6M.
The 10-Q provides Replimune Group, Inc.'s quarterly financial update, including unaudited financial statements and management commentary on recent performance. While less detailed than the annual 10-K, the 10-Q often contains timely information about emerging trends, updated risk factors, and changes in business conditions since the last filing.
All SEC filings for Replimune Group, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View REPL Stock Page
Frequently Asked Questions
Where can I read REPL's SEC filings?
Browse all filings on our REPL SEC filings page.
What types of SEC filings does Replimune Group, Inc. file?
Public companies like Replimune Group, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.